MIAMI, Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 (BIIB121) in Angelman syndrome. ION582 was generally well tolerated in the study and showed encouraging electroencephalogram (EEG) activity trends and early signals of positive clinical improvement, which will need to be confirmed upon analysis of the full data set in mid-2024. The findings were presented today at the FAST (Foundation for Angelman Syndrome Therapeutics) Summit; the presentation is available here. Part 1 of the HALOS trial is a three-month, open-label, multiple-ascending dose study. Part 2 is a long-term extension study, which will evaluate ION582 for an additional 12 months.
https://www.prnewswire.com/news-rel...f-ion582-for-angelman-syndrome-301985239.html
- Forums
- ASX - By Stock
- THE COMPETITION OF 2591
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.00%
!
$13.88

MIAMI, Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc....
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.88 |
Change
-0.140(1.00%) |
Mkt cap ! $1.727B |
Open | High | Low | Value | Volume |
$13.90 | $14.21 | $13.64 | $4.590M | 329.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 600 | $13.85 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.96 | 2894 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 600 | 13.850 |
1 | 2500 | 13.770 |
1 | 581 | 13.760 |
1 | 377 | 13.750 |
1 | 2500 | 13.700 |
Price($) | Vol. | No. |
---|---|---|
13.960 | 2894 | 1 |
14.000 | 2800 | 2 |
14.160 | 2500 | 1 |
14.180 | 1500 | 1 |
14.200 | 2500 | 1 |
Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |